Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 3/20 | 0.53 |
| ▸ | HTR1B | P28222 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056399 | 0.89 | GABRA1 (0.56) | HTR1DHTR1BHTR1AGABRA1GABRB2 | |
| SCHEMBL6819310 | 0.87 | CYP2A6 (0.58) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL29957436 | 0.87 | CYP2A6 (0.58) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL5814027 | 0.83 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL13592398 | 0.83 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL7856276 | 0.83 | ALDH1A1 (0.61) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL15902174 | 0.83 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL7229792 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2C19HTR1DHTR1B | |
| SCHEMBL8746137 | 0.81 | CYP2A6 (0.57) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 | |
| SCHEMBL27983756 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2C19CYP2A6IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014143125-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | ALDH1A1 1456/4885CYP1A2 1397/4885CYP2C19 2544/4885 |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | ALDH1A1 903/4885CYP1A2 276/4885CYP2C19 9/4885 |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | ALDH1A1 1456/4885CYP1A2 1397/4885CYP2C19 2544/4885 |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | ALDH1A1 1456/4885CYP1A2 1397/4885CYP2C19 2544/4885 |
| US-10653670-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | ALDH1A1 1456/4885CYP1A2 1397/4885CYP2C19 2544/4885 |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | ALDH1A1 1456/4885CYP1A2 1397/4885CYP2C19 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.